Search Within

Ross Levine

  1. "Center for Molecular Imaging and Biotechnology"
Formats
  1. Journal Article (202)
  2. Meeting Abstract (194)
  3. Editorial (11)
  4. Review (9)
  5. Research Letter (5)
  6. Book Section (2)
  7. Guidelines (2)
  8. Book Whole (1)
Groups
  1. Adult Leukemia (426)
  2. Center for Hematologic Malignancies (426)
  3. Center for Molecular Imaging and Biotechnology (426)
  4. Department of Medicine (426)
  5. Executive Committee, Center for Hematologic Malignancies (426)
  6. GSK Faculty (426)

More Groups

People
  1. Martin Tallman (50)
  2. Raajit Rampal (43)
  3. Eytan Stein (40)
  4. Franck Rapaport (28)
  5. Alan Shih (26)
  6. Maria Kleppe (26)

More People

Years
  1. 2024 (9)
  2. 2023 (26)
  3. 2022 (22)
  4. 2021 (25)
  5. 2020 (30)
  6. 2019 (29)

More Years

Publications
  1. Blood (159)
  2. Leukemia (16)
  3. Haematologica (14)
  4. Blood Advances (13)
  5. Cancer Research (12)
  6. Swiss Medical Weekly (11)

More Publications

Publishers
  1. American Society of Hematology (174)
  2. Nature Publishing Group (46)
  3. American Association for Cancer Research (36)
  4. Cell Press (25)
  5. Elsevier Inc. (15)
  6. Ferrata Storti Foundation (14)

More Publishers

Results (426)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Escape from type II JAK2 inhibition in MPN depends on AXL/MAPK activation and is targetable
    Meeting Abstract

    Codilupi, T.; Szybinski, J.; Brkic, S.; Stivala, S.; Yang, J.; Ghosh, N.; Buczak, K.; Passweg, J.; Angelillo-Scherrer, A.; Dirnhofer, S.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • A risk-adapted study to assess the efficacy of enasidenib and subsequent response-driven addition of azacitidine for newly diagnosed IDH2-mutant AML patients: 3-year follow-up
    Meeting Abstract

    Stein, E.; Cai, S. F.; Huang, Y.; Dunbar, A.; Baer, M. R.; Stock, W.; Kovacsovics, T.; Blum, W. G.; Schiller, G. J.; Olin, R. L.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • JAK2(V617F) reversible activation shows an essential requirement for JAK2(V617F) in myeloproliferative neoplasms (MPNs)
    Meeting Abstract

    Dunbar, A.; Bowman, R. L.; Park, Y.; Izzo, F.; Myers, R. M.; Karzai, A.; Kim, W. J.; Maestre, I. F.; Waarts, M. R.; Nazir, A.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
    Guidelines

    Döhner, H.; Wei, A. H.; Appelbaum, F. R.; Craddock, C.; DiNardo, C. D.; Dombret, H.; Ebert, B. L.; Fenaux, P.; Godley, L. A.; Hasserjian, R. P.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Resistenz auf typ II JAK2 inhibition via persistente MAPK aktivierung kann durch MEK inhibition überwunden werden
    Meeting Abstract

    Codilupi, T.; Szybinski, J.; Brkic, S.; Stivala, S.; Yang, J. L.; Wicki, A.; Ghosh, N.; Passweg, J.; Dirnhofer, S.; Levine, R. L.; more...
    Oncology Research and Treatment (2022)

    Fulltext@MSK | Save
  • A phase 1b/2 study of TP-0903 and decitabine targeting mutant TP53 and/or complex karyotype in patients with untreated acute myeloid leukemia ≥ age 60 years: Phase 1b interim results
    Meeting Abstract

    Mims, A. S.; Huang, Y.; Eisenmann, E.; Buelow, D.; Swords, R. T.; Foster, M. C.; Lin, T. L.; Baer, M. R.; Kovacsovics, T.; Al-Mansour, Z.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • PU.1-dependent enhancer inhibition separates Tet2-deficient hematopoiesis from malignant transformation
    Journal Article

    Aivalioti, M. M.; Bartholdy, B. A.; Pradhan, K.; Bhagat, T. D.; Zintiridou, A.; Jeong, J. J.; Thiruthuvanathan, V. J.; Pujato, M.; Paranjpe, A.; Zhang, C.; more...
    Blood Cancer Discovery (2022)

    Fulltext@MSK | Save
  • Integrative analysis identifies an older female-linked AML patient group with better risk in ECOG-ACRIN Cancer Research Group’s clinical trial E3999
    Research Letter

    Rapaport, F.; Seier, K.; Neelamraju, Y.; Hassane, D.; Baslan, T.; Gildea, D. T.; Haddox, S.; Lee, T.; Murdock, H. M.; Sheridan, C.; more...
    Blood Cancer Journal (2022)

    Fulltext@MSK | Save
  • Harnessing the power of sphingolipids: Prospects for acute myeloid leukemia
    Review

    Ung, J.; Tan, S. F.; Fox, T. E.; Shaw, J. J. P.; Vass, L. R.; Costa-Pinheiro, P.; Garrett-Bakelman, F. E.; Keng, M. K.; Sharma, A.; Claxton, D. F.; more...
    Blood Reviews (2022)

    Fulltext@MSK | Save
  • The ERK2-DBP domain opposes pathogenesis of a mouse JAK2V617F-driven myeloproliferative neoplasm
    Journal Article

    Zhang, Y.; Truong, B.; Fahl, S. P.; Martinez, E.; Cai, K. Q.; Al-Saleem, E. D.; Gong, Y.; Liebermann, D. A.; Soboloff, J.; Dunbrack, R.; more...
    Blood (2022)

    Fulltext@MSK | Save